Company intelligence / Profile preview

Jacobus Pharmaceutical Company Inc.

Princeton/Plainsboro, New Jersey, United Statesorpha.net ↗

Ownership: Private
Development stage: Commercial

Overview

Jacobus Pharmaceutical has developed amifampridine (3,4-DAP) for Lambert-Eaton Myasthenic Syndrome (LEMS), which was marketed as Ruzurgi. However, the FDA withdrew approval following a court ruling that it violated Catalyst Pharmaceuticals' orphan drug exclusivity for FIRDAPSE. In July 2022, Jacobus settled patent litigation with Catalyst Pharmaceuticals.

Therapeutic areas: GastroenterologyDermatologyNeurologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

WR99210

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Settlement agreement with Catalyst Pharmaceuticals in 2022

Beyond the preview

Go deeper on Jacobus Pharmaceutical Company Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jacobus Pharmaceutical Company Inc..

Explore the full profile